Medtronic PLC Management Briefing for Investors & Analysts from ADA Transcript
All right. We're going to get started. Good afternoon, everyone, and good evening to those of you joining on the East Coast and in Europe, and good morning to those joining from Asia and Australia. I'm Ryan Weispfenning, Vice President and Head of Investor Relations at Medtronic.
Thanks for joining us for our virtual Diabetes Group investor briefing to discuss our diabetes business and the clinical data that is being released in connection with the American Diabetes Association 80th Scientific Sessions virtual meeting.
While we're not together in Chicago as originally planned today, I do hope everyone is staying safe, and our thoughts continue to go out to those that have been affected by the global COVID-19 pandemic.
So switching to the next slide here. Okay. I want to note that we could make some comments that may be considered forward-looking statements and actual results might differ materially from those projected in any forward-looking statement, given risks and uncertainties, including those related to the impact COVID-19 has
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |